Citi analyst Joanne Wuensch initiated coverage of Edwards Lifesciences with a Buy rating and $252 price target. The analyst said the focus of the company is on their TAVR and TMTT franchises -- which she called large, growing market opportunities -- noting that the TAVR market is expected to increase to reach $7B in 2024 from $4B today and the TMTT market expected...
2hr on the left and daily on the right
EW is a very solid stock & company. It's beat every earnings estimate since Q1 2018.
Get it cheap while you can, oversold right now, good entry potential
System T Performances: Annual Compound Profit 40%, Win Rate 55%, Risk/Reward Ratio 1:2, 20 Years of Backtesting Data, Over 100 Markets.
* Click Like and Follow to Support My Work!
---
Hi Traders,
I'd like to introduce the System T, a computerized trading system that analyzed and backtested the 20 years history data of over 100 markets.
This post is my sharing...
NYSE:EW
Does the technical analysis work?
Look at this!
The important thing is to let the profits run and quickly cut the losses when the trend turns against you.
How would your account behave after 100 trades if 6/10 make a loss and 4/10 make a profit? The answer in the Risk Reward is how much you earn when the trade makes a profit, and that's where the...
While Pharmaceutical and Biopharma stocks have been taking a beating in 2018/19 medical device makers are on a roll , they are in one of the hottest trends in the market, seemingly bullet proof from they bears. NYSE:EW is on a perfect trend for 2 years and as earnings approach on the 23rd July it looks like a real good bet to move higher.
Indicators are all...
Its always good to brush up on our trading rules. One rule I live by is that past resistance acts as future support, in case you couldn't tell by the chart! In late June the price was met with resistance at $154. After retracing and testing support again, the stock is ready to try again. If the price does bust above previous resistance @$154 I'd expect a move up...
